Inadequate understanding of the mechanisms underlying the development of severe symptoms has limited our ability to reduce symptom burden during aggressive cancer therapy. The cytokine response in animal models of "sickness behavior" demonstrates how increased systemic inflammation induces behaviors that resemble the symptoms patients report when they receive cancer treatment, suggesting a model for studying inflammation as a potential mechanism underlying the production of severe treatmentrelated symptoms. We demonstrate in this longitudinal study that serum interleukin-6 and a variety of inflammatory changes were temporally related to the most-severe symptoms (fatigue, poor appetite, pain, distress, disturbed sleep) in the acute phase (first 30 days) after autologous stem cell transplant for multiple myeloma. These findings raise the possibility that modulating components of inflammation during the acute phase of aggressive therapy may modulate treatment-related symptoms, so long as this can be done without compromising tumor control. Results: Fatigue, pain, disturbed sleep, lack of appetite, and drowsiness were consistently the mostsevere MDASI-MM symptoms during the study. Peak symptom severity occurred on day 8 post-AuSCT, during white blood cell count nadir. Patterns of serum IL-6 (peak on day 9) and sIL-6R (nadir on day 8) expression paralleled symptom development over time (both P < 0.0001). By univariate analysis, serum IL-6, sIL-6R, IL-10, CRP, MIP-1α, sIL-1R2, sIL-1RA, and sTNF-R1 were significantly related to the mostsevere symptoms during the first 30 days post-AuSCT (all P < 0.05). By multivariate analysis, IL-6 (estimate = 0.170, P = 0.004) and MIP-1α (estimate = -0.172, P = 0.006) were temporally associated with the severity of the component symptom score.
Introduction
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AuSCT) has become part of the standard treatment regimen for patients with multiple myeloma (MM) (1) . As aggressive cancer therapies, both AuSCT and allogeneic stem cell transplant (AlloSCT) are associated with the occurrence of high symptom burden in the initial weeks posttransplant, including fatigue, pain, disturbed sleep, poor appetite, and drowsiness (2, 3), despite the differences in therapeutic agents and stem cell sources. These symptoms are difficult to manage, due in part to limited knowledge of the pathophysiology underlying their development.
Mounting evidence from both animal models and human research suggests that dysregulation of inflammatory processes may play a pivotal role in producing chronic systemic conditions, such as poor appetite, pain, fatigue, and disturbed sleep (4) (5) (6) . Our studies of patients who rapidly developed severe symptoms in response to aggressive cancer therapy (chemoradiation for gastrointestinal or lung cancer and AlloSCT for hematological malignancies) have shown that a significant increase in serum inflammatory cytokines such as interleukin (IL)-6 and soluble tumor necrosis factor receptor (sTNF-R1) is temporally associated with the development of severe symptoms during treatment (3, 7, 8) . Consistent behavioral observations in these clinical studies parallel the cytokine-induced sickness behaviors, such as hyperalgesia, disturbed sleep, reduced water and food intake, and lack of activity, seen in animal models (5) .
In the current study, we studied patients with MM undergoing high-dose chemotherapy with
AuSCT by temporally tracking changes in inflammatory markers and their relationship with the development of severe symptoms. AuSCT presents a unique opportunity for studying the cytokine dysregulation induced by high-dose chemotherapy without interference from the acute graft-versus-host response associated with AlloSCT (3). The study was approved by the MD Anderson Institutional Review Board and all participants gave written informed consent. The study is registered at ClinicalTrials.gov (NCT00688168).
Multisymptom assessment
The M. D. Anderson Symptom Inventory (MDASI) assesses the severity of 13 common cancerrelated symptoms (pain, fatigue, nausea, vomiting, dry mouth, shortness of breath, lack of appetite, difficulty remembering, drowsiness, disturbed sleep, sadness, distress, and numbness) and 6 items related to symptom interference with functioning (11) . For this study, we used the psychometrically validated multiple myeloma module of the MDASI (MDASI-MM), which contains the 19 MDASI items plus 7 MM-specific items (bone aches, muscle weakness, sore mouth/throat, rash, difficulty concentrating, constipation, diarrhea) (12) .
Patients rated symptom severity over the previous 24 hours on a 0-10 scale ranging from "not present" to "as bad as you can imagine." MDASI-MM assessments were conducted at baseline (18 days before the transplant [day -18]), twice a week from baseline to 30 days post-AuSCT (day +30), and then weekly until 100 days post-AuSCT (day +100). The assessments were completed on paper or, when the patient was unavailable in person, via phone interview with study staff.
Research. 
Inflammatory marker assay
We assessed IL-1β, soluble IL-1 receptor antagonist (sIL-1RA), soluble IL-1 receptors 1 (sIL-1R1)   and 2 (sIL-1R2), soluble IL-2 receptor antagonist (sIL-2RA), IL-4, IL-6 and its soluble receptor sIL-6R, IL-8, IL-10, IL-12p70, IL-17, tumor necrosis factor (TNF)-α, sTNF-R1, sTNF-R2, interferon (IFN)-γ, C-reactive protein (CRP), vascular endothelial growth factor (VEGF), macrophage inflammatory protein (MIP)-1α, and monocyte chemotactic protein (MCP)-1. These inflammatory markers have been identified as potentially relevant in animal and human sickness-behavior studies (3, 5, 6, 13, 14) .
Blood draws without anticoagulant were scheduled for the morning on the day of apheresis, at mobilization and conditioning day, twice a week from stem cell transplant (day 0) to day +30, and at routine clinic visits thereafter to day +100. After serum isolation by centrifugation (2-4 hours after phlebotomy), the samples were stored at −80°C for batch analysis. Inflammatory markers were measured in 25 μL of serum using MILLIPLEX MAP assays (EMD Millipore Corporation, Billerica, MA, USA) and a 
Statistical analysis
To analyze the development of patient-reported symptom outcomes in relation to objective measures, we constructed Loess curves to depict the mean level of symptom severity, WBC count, and serum inflammatory marker levels from baseline to day +100 post-AuSCT (where day of stem cell transplant was designated as day 0). Nonlinear mixed modeling was used to determine WBC nadir, symptom peaks, and the peaks and nadirs in serum levels of inflammatory markers from baseline to day +30. Statistical significance was set at 0.0038 (0.05/13.00) to adjust for multiple comparisons. We focused on the first 30 days posttransplant because most of the marker samples were collected during that time period and because graphed data for most of the symptoms and markers plateaued after day +30. Mean MDASI-MM symptom severities and mean inflammatory marker concentrations between the day -18 to day +30 period (before and the first month after AuSCT) and the period of symptom and marker plateau (day +31 to day +100) were reviewed using the Wilcoxon rank sum test.
Descriptive analysis was used to present patient characteristics. Markers for which more than 10% of the samples had undetectable values were not included in the analysis. For each marker retained for analysis, samples with undetectable values were imputed to have one-half the lowest nonzero value from the detectable samples for that marker. To give context to the variability of the cytokine assay and symptoms, a waterfall plot was constructed to examine the changes in the 5 most-severe symptoms and in serum IL-6 levels from baseline to nadir (16).
To determine the relationship of the strength of inflammatory changes and increases in symptom severity, mixed-effect models were constructed to identify the critical serum inflammatory marker(s) that were temporally associated with symptoms with dynamic changes in the first 30 days, included as timedependent variables (17). We used both MDASI-MM single-symptom scores and a mean component score of the 5 most-severe symptoms as outcome measures for each patient. Time-independent variables that might have an impact on symptom or inflammatory response (age, sex, cancer stage, bortezomib induction treatment status, stem cell dose, baseline mood score, and BMI) were included in all models. The baseline mood score was the average of pre-AuSCT MDASI-MM "sadness" and "distress" scores, based on a previous study by McGregor et al. (18) indicating that distress had a significant effect on blood count recovery. Each inflammatory marker was included in a univariate model on a transformed natural log scale. Those that showed significant effects at P < 0.05 in the univariate models were included in a multivariate model for each symptom outcome. Statistical significance for each multivariate model was set as 0.05/n (where n = the number of cytokines included in the model). Estimates were calculated for natural log transformed inflammatory marker variables to show how the symptom outcome would change when the marker changed by any ratio. 
Results

Patient and treatment characteristics
Of 70 eligible patients, 7 declined to participate. Table 1 
Patterns of symptom development
The overall missing-data rate for MDASI-MM symptom ratings was 7% between baseline and day +30 and 15% between days +31 and +100, stemming primarily from missed follow-up calls to patients.
Comparing average mean MDASI-MM scores from baseline to day +30, the 5 most-severe symptoms were fatigue, disturbed sleep, pain, lack of appetite, and drowsiness; this ranking remained consistent throughout the study.
Loess curves present the average WBC count and the projected severity of these 5 symptoms on a 0-10 scale from baseline to day +100 (Fig. 1) . Mixed-effects modeling demonstrated that lack of appetite displayed the largest change over time (linear terms for days since AuSCT, estimate = 3.86, standard error of the mean = 0.42, P < 0.0001). We also examined day of peak symptom severity for the 5 most-severe symptoms during the first 30 days post-AuSCT (Table 2 ). The individual symptoms and the component score showed significant peaks around day +8. Pain, one of the most-severe symptoms, remained relatively constant over the observation period.
Serum inflammatory marker patterns over time
All cytokines that were below the limit of detection in more than 10% of the samples were excluded from the analysis. MCP-1, IL-8, TNF-α, sIL-1RA, sIL-1R2, sIL-2RA, sIL-6R, sTNF-R1, sTNF-R2, and CRP (each undetectable in <2% of the samples), MIP-1α (5.5%), IL-10 (6.5%), and IL-6 (9%) were included in the analyses.
Loess curves depict the average levels of inflammatory markers from baseline to day +100 (Fig.   2 ). The markers presented in the figure were those found to have significant associations with symptom outcomes in both the univariate and multivariate analyses. Table 3 shows that the 13 testable inflammatory markers reached peak or nadir on various days post-AuSCT. Because of these fluctuations, we concentrated on data from baseline to day +30 using nonlinear mixed modeling. Significant peak values were detected for IL-6 on day +9, CRP on day +13, and IL-10 on day +18 (all P < 0.0001). A significant nadir was seen for sIL-6R on day +8 (P < 0.0001) and for sIL-1RA on day +5 (P = 0.003).
No significant peak or nadir was found for IL-8; however, Wilcoxon rank sum test showed significantly lower levels of IL-8 during the first 30 days post-AuSCT than from day +31 to day +100 (P = 0.0003). Significantly higher concentrations of sTNF-R1 (P = 0.006) and sIL-2RA (P < 0.0001) were found in the first 30 days post-AuSCT than in the later period. No significant change over time was observed for MCP-1, sIL-1R2, or TNF-α.
Associations between inflammatory markers and symptom severity Univariate analysis identified serum IL-6, sIL-6R, IL-10, CRP, MIP-1α, sIL-1R2, and sTNF-R1 (all P < 0.05) as significantly related to 1 or more of the 5 most-severe symptoms during the first 30 days after AuSCT (Table 4) 
mood score, and cancer stage were used as covariates, but there was no observed significant effect on symptom outcomes. The identified markers were retained as candidates for the multivariate analysis.
The multivariate analysis (mixed effect modeling) identified IL-6 (P = 0.001) and MIP-1α (P = 0.013) as the critical inflammatory markers related to the development of the 5 most-severe symptom outcomes during the first 30 days post-AuSCT, controlling for the same set of covariates. Worse preAuSCT mood score was significantly associated with more-severe symptom outcomes (P = 0.003). The other covariates did not have a significant effect.
For individual symptom outcomes, we found significant positive relationships between change in IL-6 concentration level and change in drowsiness (P = 0.009) and between sTNF-R1 (P = 0.004) and IL-10 (P = 0.01) related to higher pain severity; inverse relationships were found between MIP-1α and disturbed sleep (P = 0.0002), and sIL-6R and fatigue (P = 0.039). Pre-AuSCT mood score was the only patient or clinical factor significantly related to changes in symptom severity (fatigue and drowsiness), although younger patients (≤60 years of age) consistently reported more severe pain than did older patients across the observation period (estimate = 0.106, P = 0.007).
Discussion
The current study suggests that IL-6 plays an important role in the development of high symptom burden during the initial month after stem cell transplant (4, 13, 19, 20) . A cluster of symptoms (fatigue, disturbed sleep, lack of appetite, pain, and drowsiness) was consistently the most severe among all MDASI-MM symptoms assessed from day -18 to day +100 of AuSCT. Methodologically, our longitudinal study was sufficiently powered to utilize mixed-effects modeling to detect the temporal association between symptom scores and expression of inflammatory markers, while controlling for confounding variables (17, 24-26).
A high-dose melphalan conditioning regimen triggers a severe drop in WBC count and a resulting deficiency that could lead to infectious complications. This, along with residual disease, psychological distress, and prolonged side effects from induction therapy, could contribute to inflammatory and symptom responses. Regardless of the effect of these factors, patients collectively shared not only the same severe symptoms, but also a similar symptom trajectory that was at its worst at WBC nadir postAuSCT. There was no significant change over time in pain severity, but because pain was persistently severe compared with other symptoms, we included it in the symptom component score.
The univariate analysis identified that serum IL-6, sIL-6R, IL-10, CRP, MIP-1α, sIL-1R2, and sTNF-R1 were significantly related to development of the 5 most-severe symptoms during the same period. In examining the timing of peak or nadir of inflammatory marker expression compared with the peak in symptom burden at day +8 during WBC nadir (range, day 4-10), we observed the closest correlations for IL-6 (positively) and IL-6R and MIP-1α (inversely). IL-6 has been identified as a primary marker associated with symptom-burden peak in both AuSCT and AlloSCT, which suggests that its role is more relevant to the nadir effect caused by treatment than to disease during the critical first month posttransplant, although IL-6 is a well-known disease growth factor in MM (21). In view of the low WBC count, it is possible that the immune system is not the source of IL-6; IL-6 might alternatively be produced by other organ cells such as hepatocytes or endothelial cells. sIL-1RA had an earlier nadir (day +5) than the symptom peak and a more-rapid decline than IL-6, indicating a more-sensitive response to the transplant. To our knowledge, our study is the first to identify inverse associations between sIL-6R and IL-6 and between sIL-6R and fatigue severity. sIL6R is known to increase IL-6-induced signaling by forming a complex with IL-6 and gp130 on the membranes of cells. The decrease in the level of sIL-6R may protect the individual from even more proinflammatory signaling and subsequent development of moresevere symptoms.
How circulating cytokines signal the brain to trigger multiple severe symptoms in humans is unknown, although in animal studies it has been demonstrated that systemic cytokine production can influence behavior by inducing symptoms of sickness and depression (5, 22) . Further, we cannot explain why levels of either TNF-α or its receptors were unchanged at the time point of chemotherapy-induced WBC nadir. Given that the peak response of CRP and IL-10 occurred after the symptom peak, these mediators are unlikely to initiate the development of severe symptoms (23).
The study has several limitations. We designed our study to coincide with patients' routine blooddraw schedules, so as to reduce the likelihood of missing data. Therefore, the timing of blood draws during the day may not have been consistently optimal and could have been affected by circadian patterns of cytokine release. Also, we collected a limited number of samples (totaling approximately 15% of all samples) during the day +30 to +100 period, due to fewer regularly scheduled follow-up visits during this time period. Finally, samples were kept for 2 to 4 hours at room temperature but were not tested for stability thereafter; this approach should be examined in future studies, as many cytokines are unstable.
Additional studies might also examine observer-rated transplant-associated toxicities to gain a better understanding of such toxicities and symptom burden.
In summary, defining the temporal development of inflammatory activity in concert with the development of high symptom burden is another step toward establishing a better understanding of the nature of treatment-induced symptom burden. Anti-inflammatory intervention may be further tested in clinical studies to establish the role of inflammation inhibition in relation to amelioration of severe symptoms, so long as this can be done without compromising the efficacy of the antitumor treatment.
Reduction of therapy-associated symptoms should make cancer treatment more tolerable and therefore more accessible to those patients who might not otherwise be considered for aggressive cancer therapy. The estimate is a parameter estimated for a predictor. For natural log transformed independent variables, the estimate shows how the outcome changes when the predictor changes by any ratio. For example, the estimate of natural log IL-6 levels for the mean severity of the top 5 symptoms was 0.196, which meant that when the level of IL-6 doubled (or increased 100%), there was a corresponding 0.196*log2 = 0.14-unit increase in the mean symptom score.
